49 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
AMGN Amgen Inc. $200.81 $129.98B N/A
Article Searches
Sanofi (SNY) Q4 Earnings Top, Sales Miss, Dupixent Strong http://www.zacks.com/stock/news/752611/sanofi-sny-q4-earnings-top-sales-miss-dupixent-strong?cid=CS-ZC-FT-analyst_blog|earnings_article-752611 Feb 06, 2020 - Sanofi (SNY) reports mixed fourth-quarter results with strong Specialty Care and Vaccines sales but soft Consumer Healthcare sales
Bristol-Myers' (BMY) Q4 Earnings & Revenues Beat Estimates http://www.zacks.com/stock/news/753057/bristol-myers-bmy-q4-earnings-revenues-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-753057 Feb 06, 2020 - Bristol-Myers (BMY) beats both earnings and sales estimates in the fourth quarter, primarily on robust sales of Eliquis and acquisition of Celgene.
Top Stock Research Reports for Alphabet, Roche & Amgen http://www.zacks.com/research-daily/754489/top-stock-research-reports-for-alphabet-roche-amgen?cid=CS-ZC-FT-research_daily-754489 Feb 07, 2020 - Top Stock Research Reports for Alphabet, Roche & Amgen
Teva (TEVA) to Report Q4 Earnings: What's in the Cards? http://www.zacks.com/stock/news/754447/teva-teva-to-report-q4-earnings-whats-in-the-cards?cid=CS-ZC-FT-analyst_blog|earnings_preview-754447 Feb 07, 2020 - Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q4 sales.
Roche Reports Disappointing Data on Alzheimer's Disease Drug http://www.zacks.com/stock/news/758962/roche-reports-disappointing-data-on-alzheimers-disease-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-758962 Feb 10, 2020 - Roche's (RHHBY) Alzheimer's disease drug fails to meet primary endpoint in a phase II/III study.
Novartis (NVS) to Acquire The Medicines Company for $9.7B http://www.zacks.com/stock/news/636880/novartis-nvs-to-acquire-the-medicines-company-for-%2497b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-636880 Nov 25, 2019 - Novartis (NVS) set to acquire The Medicines Company and add a promising candidate to its cardiovascular pipeline.
Merck's Keytruda Gets Nod in China for Difficult Lung Cancer http://www.zacks.com/stock/news/643382/mercks-keytruda-gets-nod-in-china-for-difficult-lung-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-643382 Nov 27, 2019 - Merck (MRK) receives the third approval of Keytruda for first-line non-small cell lung cancer patient population in China.
Why Novartis's $9.7 Billion Purchase of The Medicines Company Is Bad News for Amgen https://www.fool.com/investing/2019/12/02/why-novartis-97-billion-purchase-of-the-medicines.aspx?source=iedfolrf0000001 Dec 02, 2019 - Novartis's purchase comes with investigational cardiovascular drug inclisiran, a competitor with potential to dethrone Amgen's already embattled Repatha.
Biogen Up on New Data on Alzheimer's Candidate Aducanumab http://www.zacks.com/stock/news/657638/biogen-up-on-new-data-on-alzheimers-candidate-aducanumab?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-657638 Dec 06, 2019 - Biogen (BIIB) divulges new positive data on Alzheimer's candidate, aducanumab at CTAD. Stock rises.
Biotech ETFs Hit New Highs on Deal Activities http://www.zacks.com/stock/news/663878/biotech-etfs-hit-new-highs-on-deal-activities?cid=CS-ZC-FT-etf_news_and_commentary-663878 Dec 10, 2019 - Following the new deals in the healthcare space, a few biotech ETFs hit new highs.

Pages: 12345

<<<Page 3>